Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Apr 7:5:26.
doi: 10.1186/1748-717X-5-26.

Early administration of IL-6RA does not prevent radiation-induced lung injury in mice

Toshiyuki Ogata  1 , Hideya Yamazaki, Teruki Teshima, Ayaka Kihara, Yuko Suzumoto, Takehiro Inoue, Norihiro Nishimoto, Nariaki Matsuura
Affiliations

Early administration of IL-6RA does not prevent radiation-induced lung injury in mice

Toshiyuki Ogata et al. Radiat Oncol. .

Abstract

Background: Radiation pneumonia and subsequent radiation lung fibrosis are major dose-limiting complications for patients undergoing thoracic radiotherapy. Interleukin-6 (IL-6) is a pleiotropic cytokine and plays important roles in the regulation of immune response and inflammation. The purpose of this study was to investigate whether anti-IL-6 monoclonal receptor antibody (IL-6RA) could ameliorate radiation-induced lung injury in mice.

Methods: BALB/cAnNCrj mice having received thoracic irradiation of 21 Gy were injected intraperitoneally with IL-6RA (MR16-1) or control rat IgG twice, immediately and seven days after irradiation. Enzyme-linked immunosorbent assay was used to examine the plasma level of IL-6 and serum amyloid A (SAA). Lung injury was assessed by histological staining with haematoxylin and eosin or Azan, measuring lung weight, and hydroxyproline.

Results: The mice treated with IL-6RA did not survive significantly longer than the rat IgG control. We observed marked up-regulation of IL-6 in mice treated with IL-6RA 150 days after irradiation, whereas IL-6RA temporarily suppressed early radiation-induced increase in the IL-6 release level. Histopathologic assessment showed no differences in lung section or lung weight between mice treated with IL-6RA and control.

Conclusions: Our findings suggest that early treatment with IL-6RA after irradiation alone does not protect against radiation-induced lung injury.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meier analysis of survival curves and body weights for IL-6RA- (white circle) and IgG control (black circle)-injected mice. (A) Survival curves. The p value was calculated with the log-rank test. Kaplan-Meier plots were calculated from data for 7 IL-6RA-treated mice and 8 nontreated mice. (B) Body weights. Data are presented as means + SD.
Figure 2
Figure 2
Effects of IL-6RA treatment in lungs of lethally irradiated IL-6RA (white square) and IgG control (black square) mice on radiation-induced increases in IL-6 (A) and SAA (B) production. Each bar represents the mean ± SD (n = 5 per group). Asterisks indicate statistical significance. Dotted line represents each from average value of non-irradiated mice + SD to average value of them -SD.
Figure 3
Figure 3
Effects of IL-6RA treatment on radiation-induced lung injury indices. (A) Lung weight after 21 Gy of single irradiation to whole thorax with (white square) or without (black square) IL-6RA treatment. (B) Hydroxyproline levels in lung homogenates obtained from IL-6RA injected mice (white square) or control (black square). Data obtained from 5 animals in each group are presented as means ± SD. Dotted line shows each from mean value of non-irradiated mice + SD to mean value of them -SD.
Figure 4
Figure 4
Histological analyses using H&E staining for irradiated murine lung tissue.
Figure 5
Figure 5
Histological analyses using Azan staining for irradiated murine lung tissue.
See this image and copyright information in PMC

References

    1. Mehta V. Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: pulmonary function, prediction, and prevention. Int J Radiat Oncol Biol Phys. 2005;63:5–24. - PubMed
    1. Yu TK, Whitman GJ, Thames HD, Buzdar AU, Strom EA, Perkins GH, Schechter NR, McNeese MD, Kau SW, Thomas ES, Hortobagyi GN, Buchholz TA. Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients. J Natl Cancer Inst. 2004;96:1676–1681. - PubMed
    1. Tsoutsou PG, Koukourakis MI. Radiation pneumonitis and fibrosis: mechanisms underlying its pathogenesis and implications for future research. Int J Radiat Oncol Biol Phys. 2006;66:1281–1293. - PubMed
    1. Brush J, Lipnick SL, Phillips T, Sitko J, McDonald JT, McBride WH. Molecular mechanisms of late normal tissue injury. Semin Radiat Oncol. 2007;17:121–130. doi: 10.1016/j.semradonc.2006.11.008. - DOI - PubMed
    1. Rubin P, Johnston CJ, Williams JP, McDonald S, Finkelstein JN. A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. Int J Radiat Oncol Biol Phys. 1995;33:99–109. - PubMed

MeSH terms